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Summary
Objective: To compare the performance of two tests for diagnosing latent tuberculosis (TB)
infection in the HIV-positive population in Chile, in order to better identify the subjects who
might benefit from TB chemoprophylaxis.
Design: This was a cross-sectional study among individuals attending three HIV outpatient clinics
in Santiago, tested with a 2-TU purified protein derivative, QuantiFERON1-TB Gold ‘in-tube’
(QFT-G), and a chest X-ray.
Results: A total of 116 subjects were enrolled in the study, having amean CD4 count of 393 cells/ml
(range 100—977). The tuberculin skin text (TST; 5 mm cutoff) and QFT-G results were positive in
10.9% and 14.8% of the individuals, respectively, with moderate agreement between both tests
(kappa = 0.59). A history of both known TB exposure (odds ratio (OR) 3.46, 95% confidence interval
(CI) 1.02—11.22) and past TB (OR 4.31, 95% CI 1.13—15.5) were associated with a positive QFT-G
result. Only past TB was significantly associated with a positive TST result (OR 6.63, 95% CI 1.62—
26.3). Among the subjects with TST < 5 mm, 8.2% were positive by QFT-G test. These individuals
had a lower mean CD4 cell count than those detected positive by both tests (328 cells/ml and
560 cells/ml, respectively, p = 0.03).
Conclusions: In this population of HIV-infected individuals, QFT-G and TST showed an acceptable
level of agreement, although QFT-G appears less affected by more advanced immunosuppression.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.§ The preliminary results of this study were presented as a poster presentation at the 45th Annual Meeting of the Infectious Diseases Society of
America, San Diego, California, USA, October 2007.
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Tuberculosis (TB) remains a major health problem worldwide.
Despite enormous public health efforts, the World Health
Organization (WHO) estimated 9.2 million new cases in
2006, ofwhich7.7%were co-infectedwithHIV.1 The tuberculin
skin test (TST) is still themost extensively used tool worldwide
for the diagnosis of latent TB in HIV-positive individuals. A
positive TST is considered a good predictor of the risk of
developing clinical TB in HIV-positive individuals, and there
is compelling evidence showing that these patients benefit
from TB chemoprophylaxis.2 However, there are several draw-
backswhen interpreting aTSTresult. The sensitivity of the test
is reduced in HIV-positive patients, especially when the CD4
cell count is less than 100 cells/ml and the possibility of an
anergic response impedes the correct interpretation of the
test.3 On the other hand, in countries where the bacille
Calmette—Gue´rin (BCG) vaccine is still widely administered,
the result of a positive TST is frequently ascribed to cross-
reactivity with proteins present in the vaccine strain. In fact it
has been shown that previous BCG vaccine increases the like-
lihood of a positive TST, especially if given within the last 15
years.4 Furthermore, TST also cross-reacts with proteins pre-
sent in Mycobacterium avium complex and other non-tuber-
culous mycobacteria.5,6 These drawbacks result in low
adherence to the testing of HIV-positive patients by clinicians
and even to their not acting on a test result, as currently
happens even in developed nations.7
In Chile, the incidence of active TB has been decreasing
steadily over the last three decades from an annual incidence
rate as high as 76/105 in the 1980s to a record rate of 13/105
in 2005.8 However, among the HIV-positive population the
number of TB cases is strikingly higher, with a prevalence of
up to of 6.8 cases per 100 individuals according to the most
recent survey.9 This situation points to a need for greater
awareness and better TB control in this group of patients.
Regretfully, TST is locally disregarded for the above-men-
tioned reasons, with less than one third of individuals attend-
ing regular HIV programs being tested.9
Alternative methods have been developed as diagnostic
tools for diagnosing latent TB infection. The whole-blood
interferon-g release assay QuantiFERON1-TB Gold (QFT-G)
was approved by the US Food and Drug Administration for
use in immunocompetent individuals in December 2005.10 The
test is based on exposing T-lymphocytes ex vivo to Mycobac-
terium tuberculosis-specific antigens (ESAT-6, CFP-10, and TB-
7.7) and after a period of incubationmeasuring the interferon-
g elaborated in response to antigen recognition. These anti-
gens are absent from the genome of Mycobacterium bovis,
BCG, M. avium, and most other non-tuberculous mycobac-
teria, with the exception of Mycobacterium kansasii, Myco-
bacterium szulgai, and Mycobacterium marinum.11—13
The specificity of interferon-g (IFN-g) assays has been
found to be as high as 98.1% in the immunocompetent
population of BCG vaccinated individuals compared to only
68.1% for TST.14,15 However the sensitivity of the test has
been more difficult to determine and it has been extrapo-
lated by active TB as the gold standard with results varying
between 64% and 87%.14,16
A small number of studies have investigated the effec-
tiveness of IFN-g-based assays in diagnosing latent TB in HIV-positive individuals.17,18 Recently, a comparative study con-
ducted in a high TB prevalence setting found better agree-
ment between TST and QFT-G in HIV-positive than in HIV-
negative individuals.19
We aimed to compare the results of QFT-G and TST in a
population of HIV-positive individuals from a low TB preva-
lence country, according to the level of immunosuppression.
We hypothesized that QFT-G would correlate better than TST
with the risk of TB infection in this group of patients, and also
that more cases of latent TB would be detected with QFT-G
than with the TST, this way helping to reduce the limitations
of the TST.
Methods
Study population
Study participants were prospectively enrolled between Jan-
uary 2006 and May 2007 at three main HIV outpatient clinics
in Santiago, Chile. These were either newly arrived patients
with a confirmed diagnosis of HIV or patients under regular
management in the clinics. The protocol was approved by the
ethics review committee of the Pontificia Universidad Cato´-
lica de Chile, and an informed consent was obtained from all
the individuals in the study.
The inclusion criteria included age >18 years, a CD4 cell
count higher than 100 cell/ml performed in the last three
months, and no previous TST within the last two years. We
included individuals who reported a history of past TB. We
excluded pregnant women, individuals on steroid therapy or
other immunosuppressants, and individuals presenting with
cough, recent weight loss, or fever ongoing at the time of
enrolment.
All the patients were interviewed following a structured
questionnaire. The following variables were considered
potential risk factors for latent TB infection: older age,
history of previous TB disease, evidence of past TB in a
chest X-ray, previous known exposure to a case of active
pulmonary TB, healthcare workers or individuals working
with homeless people, residence in prison, and long-dura-
tion stay in a country with a TB incidence higher than that
in Chile. Previous BCG vaccine, previous TST, body mass
index, previous M. avium complex disease, HIV viral load,
and mean CD4 cell count were also recorded as possible
confounders.
At each clinic, a physical examination was carried out
by the infectious diseases specialist participating in the
study.
Chest X-ray
A single-view chest X-ray was performed for all the subjects
enrolled in the study within 2 weeks of enrolment. The
radiologists, who were blind to the patient’s medical history
and test results, reviewed each chest X-ray looking for
evidence of past TB. Evidence was defined as: (a) upper lobe
pleural thickening, (b) upper lobe linear or nodular scarring
images, (c) calcified nodules (granulomas), (d) reduction in
the volume of upper lobes, (e) cranial retraction of the
pulmonary helium, and (f) calcified mediastinal and hilar
lymph nodes.
Table 1 Baseline data for all the HIV-positive individuals
included in the study (N = 116)
Age, median years (range) 38.8 (21—71)
Male sex, n (%) 99 (85.3%)
Country of residency, n (%)
Only Chile 98/112 (87.5%)
Chile and Peru (a) or Bolivia (a) 8/112 (7.1%)
Chile and other Latin American country 6/112 (5.4%)
Educational level 8 years of school, n (%) 17/105 (16.2%)
BCG scar, n (%)
None 13/109 (11.9%)
One 42/109 (38.5%)
Two 47/109 (43.1%)
Three 7/109 (6.4%)
Previous TB diagnosis, n (%) 14 (12.1%)
Previous Mycobacterium avium complex
disease, n (%)
1/102 (1.0%)
TB risk factors
Chest X-ray signs of past TB, n (%) 9 (7.8%)
Known close exposure to a TB patient 21 (18.1%)
Long term residence in a high TB
prevalence countrya
8/112 (7.1%)
Residence in prison, healthcare worker,
contact with homeless
21/113 (18.6%)
HIV status
HAART, n (%) 67 (57.8%)
CD4 cell count, mean ( SD) 393  183
CD4 cell count, n (%)
100—249 CD4 cells/ml 28/115 (24.3%)
250—499 CD4 cells/ml 62/115 (53.9%)
500 CD4 cells/ml 25/115 (21.7%)
HIV RNA viral load, n (%)
<80 copies/ml 48/97 (49.5%)
80—1000 copies/ml 9/97 (9.3%)
1000—50 000 copies/ml 23/97 (23.7%)
>50 000 copies/ml 17/97 (17.5%)
TB, tuberculosis; BCG, bacille Calmette—Gue´rin; HAART, highly
active antiretroviral therapy.
a Incidence of TB >100/100 000.Note: For factors where some
information was missing, denominators are given.
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After collection of blood samples for the IFN-g assay, the TST
was performed on the volar side of the forearm according to
the Mantoux method using a 2-TU dose of purified protein
derivative RT23 (State Serum Institute, Denmark). Skin tests
were read by an experienced and trained team of three
nurses as millimeters of induration after 72 hours, and reac-
tions 5 mm were considered positive. The nurses who
performed the TSTwere blinded to the status of all patients.
Individuals with a positive TSTwere referred to their attend-
ing physician for isoniazid preventive therapy according to
Chilean national guidelines.
IFN-g assay
The QuantiFERON-TB Gold ‘in-tube’ test (Cellestis Ltd, Aus-
tralia) was carried out at the clinical microbiology laboratory
of the Hospital Clı´nico Universidad Cato´lica, according to the
manufacturer’s instructions. First, 1 ml of blood was drawn
directly into vacutainer tubes coated with saline (negative
control), peptides of ESAT-6, CFP-10 and TB-7.7, or PHA
(mitogen control) and the tubes were incubated for 16—
24 hours at 37 8C. Then 200 ml of plasma were harvested
and frozen at  20 8C until further analysis. The concentra-
tion of IFN-g and the interpretation of test results were
determined according to the manufacturer’s instructions
(Cellestis Ltd). The investigator who performed the IFN-g
assays was blinded to the TST status of all participants.
Calculations were performed using the software provided
by the manufacturer.
Statistical analysis
We determined the agreement between the TST and IFN-g
assay results using kappa (k) coefficients (k 0.21—0.40, fair
agreement; k 0.41—0.60, moderate agreement; k 0.61—
0.80, substantial agreement).20 Univariate odds ratios
(ORs) were calculated for the potential risk factors for a
positive TST or a positive QFT-G test result. Multivariable
logistic regression analysis was performed using the stepwise
procedure to determine independent risk factors for a posi-
tive latent TB test. Continuous variables were compared by
independent samples t-test. All p values were two-tailed,
and a value of <0.05 was considered to be statistically
significant.
Results
Baseline characteristics of patients
One hundred and sixteen HIV-positive individuals were
recruited. Seven patients were excluded from paired test
results analysis due to logistical errors (five patients failed to
come back for TST reading, one patient’s TSTwas performed
before IFN-g assay blood sample, and for one patient there
was insufficient blood volume for the IFN-g assay).
The baseline characteristics of the subjects included are
shown in Table 1. The mean age was 38.8 years (range 21—71)
and 14.7% were female. The mean CD4 cell count was 393
(range 100—977) and 57.8% were under highly active anti-retroviral therapy (HAART) at enrolment in this study. A BCG
scar on the left arm was recorded in 88.1% of the cases and
49.5% of the subjects had two or more BCG scars. Nine
participants (7.8%) presented evidence of past TB in their
chest X-ray and a total of 14 individuals (12.1%) reported
having had previous TB disease.
Latent tuberculosis test results
Among the 110 individuals tested with the TST, 10.9% were
positive, with amean TST diameter of 12.2 mm (range 5—23).
Among the 115 individuals tested with QFT-G, 14.8% were
positive, with a mean interferon-g production of 5.84 mg/l
(antigen-nil values). We did not have any indeterminate
result.
Figure 1 Results of TST (mm) versus the amount of IFN-g (TB
antigen-nil value, in IU/ml) in 109 HIV-positive individuals having
paired test results.
648 M.E. Balcells et al.The correlation for the absolute amount of IFN-g produced
in response to TB antigens and TST in millimeters is shown in
Figure 1.
A total of 109 individuals had paired results for both tests
available (Table 2). We obtained a moderate agreement
between both tests, with a k value of 0.59 (95% CI 0.411—
0.775). Using a 10 mm induration cutoff for the TST resulted
in a k value of 0.385 (95% CI 0.224—0.545). The degree of
agreement of both tests also varied depending on the risk
category for previous TB exposure. Among those individuals
for whom no known risk factor for TB was found (n = 61), k
was 0.17, and among those individuals recording any known
possible latent TB risk factor (n = 45; past TB, chest X-ray
signs, past TB exposure, having lived in a TB endemic country,
or other possible environmental exposure as previously
defined), k was 0.86.
A total of 9/11 (82%) of all the TST positive cases were
confirmed by a positive QFT-G test. The two discordant cases
(TST positive/QFT-G negative) were a 35-year-old male sub-
ject with a 5 mmTSTand no known risk factor for TB and a 28-
year-old female subject with a 12 mm positive TST and
history of having received isoniazid preventive therapy for
a previous TST positive result three years ago. On the other
hand, only nine out of 17 individuals who had a positive QFT-G
were also positive with the TST. Among the eight patients
with QFT-G positive/TST negative results, three individuals
had well recognized TB risk factors: two subjects had pre-
vious close contact (at home) with a pulmonary TB patient
and had not received chemoprophylaxis and one subject
worked with homeless people in shelters during one year.Table 2 Correlation between TST and QFT-G results in HIV-
positive individuals (N = 109)
QFT-G (+) QFT-G ()
TST 5 mm 9 (81.8%) 2 (18.2%)
TST <5 mm 8 (8.2%) 90 (91.8%)
TST, tuberculin skin test; QFT-G, QuantiFERON-TB Gold ‘in-tube’.
Kappa = 0.59 (p = 0.0001).One of these individuals developed disseminated TB a month
after the positive QFT-G test result.
Latent TB test results and immunosuppression
level
As both the TST and QFT-G depend on the CD4 recognition
of M. tuberculosis antigens, we tested whether the mean
CD4 cell count differed between the individuals with a
positive and those with a negative test result. The mean
CD4 cell count differed significantly between the group of
patients having a positive TST and those with a negative
TST result (551 cells/ml and 377 cells/ml, respectively,
p = 0.02), as there was a tendency to find higher TST
readings as CD4 counts increased (Figure 2A). Those sub-
jects with a positive QFT-G also had a higher mean CD4
count than those with a negative (451 cells/ml and
381 cells/ml, respectively), but this difference did not
reach statistical significance nor was a significant trend
observed in global IFN-g responses according to the level of
CD4 count (Figure 2B).
As previously mentioned, eight patients (8.2%) were
detected as negative by TST but were nevertheless positive
by QFT-G testing. These individuals had a lower mean CD4
cell count than those detected positive simultaneously by
both tests (328 cells/ml and 560 cells/ml, respectively,
p = 0.03).
The amount of IFN-g produced in response to TB antigens
tended to be lower and closer to the cutoff in those cases
detected as positive only by QFT-G (1.78  1.77 mg/l) than
in the cases detected as positive simultaneously by TSTand
QFT-G (9.44  12.5 mg/l), but the difference did not reach
statistical significance ( p = 0.1). The IFN-g produced in
response to mitogen stimulation was also smaller in the
former group (data not shown); this difference could prob-
ably have been related to the difference in CD4 count in
both groups.
Risk factors for tuberculosis infection
In univariate analysis, a history of previous individual TB
was significantly associated with both a higher chance of a
positive QFT-G (OR 4.31, 95% CI 1.13—15.5) and a positive
TST (OR 6.63, 95% CI 1.62—26.3) (see Table 3). Referred
past exposure to a TB patient was also significantly asso-
ciated with a positive QFT-G test (OR 3.46, 95% CI 1.02—
11.22), but not significantly to a positive TST (OR 3.75, 95%
CI 0.97—13.79). None of the other possible TB risks factors
included in the analysis were significantly associated with
having a positive latent TB test, including previous TST,
which was considered a possible confounder. Also, the use
of antiretroviral therapy was not associated with a signifi-
cant difference in the proportion of patients having a
positive TST result (9.5% for naı¨ve vs. 12.1% for antiretro-
viral therapy, p = 0.7) or for those having a positive QFT-G
test result (17% for naive vs. 13.6% for antiretroviral
therapy, p = 0.62).
Multivariate logistic regression analysis confirmed that
past TB was independently associated with a positive TST
( p = 0.016) as well as a higher CD4 count ( p = 0.044). For
QFT-G, past TB was the only factor significantly associated
with a positive test result ( p = 0.041).
Figure 2 Latent TB test performance according to the mean CD4 cell count level. (A) TST (mm) versus CD4 cell count in 110 HIV-
positive subjects. (B) IFN-g (TB antigen-nil value, in IU/ml) versus CD4 cell count in 115 HIV-positive subjects.
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We found a moderately good agreement between the TSTand
QFT-G in this population of HIV-infected individuals with an
intermediate degree of immunosuppression. This result is in
accordance with the findings from the few other published
studies that have compared similar tests in HIV-positive
individuals and have found better agreement between IFN-
g assays and TST than in immunocompetent populations.19,17
In this study more positive cases were detected by QFT-G
than by TST, suggesting that QFT-G is a more sensitive tool to
diagnose latent TB. While this finding needs to be replicated
in a larger group of patients, a better sensitivity is a valuable
attribute for testing immunosuppressed patients. The cases
missed by the TST may have been due to a global anergic
response; several studies have found that TST reactivity and
TST cellular immune responses are impaired in HIV-infected
adults.19,21,22 This impairment in TB cellular immunity is
patent even after the recovery of the CD4 count under
HAART.23 A recent TB vaccine trial among HIV-positive indi-
viduals in a high TB prevalence area has found lower sensi-
tivity for the TST than for combined lymphocyte proliferationassays or IFN-g levels after stimulation with individual M.
tuberculosis-specific antigens.24 In accordance with this
data, we found fewer TST reactors with CD4 counts under
200 than with QFT-G. However, we did not investigate the
performance of the tests in individuals with very low CD4
counts, although probably more cases of anergic TST
responses and low-mitogen QFT-G responses could have been
expected to occur. The QFT-G test can also be limited in
advancing immunosuppression, and although our small num-
ber of positive cases did not allow the testing of this issue,
other authors have found a trend towards decreased posi-
tivity for QFT-G in those patients with CD4 counts <250/
mm3.19 Regretfully, the current test does not allow adjusting
of the amount of IFN-g produced to the CD4 concentration of
the blood sample.
Among the TST that resulted in a positive, 82% were also
positive by the QFT-G, which is much more than we initially
expected given that our patients are for the most part BCG
vaccinated. This high percentage of concordance of the
positive TST with a positive QFT-G result may be ascribed
to several factors. Firstly, in Chile, the BCG vaccine is still
mandatory at birth and until very recently also at four years
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650 M.E. Balcells et al.of age; however, for all of our patients a time-period of at
least 15 years had elapsed since their last BCG dose. The
boostering effect of BCG on the TST is less marked when such
a time period has elapsed between them.4 Secondly, differ-
ent degrees of exposure to environmental mycobacterial
antigens may play a crucial role in the difference in the
individual TSTresponse. Other mycobacterial diseases poten-
tially cross-reacting with TSTare not prevalent in our region,
excepting M. avium complex, for which the amount of cross-
reaction is small.5,6
In HIV-negative populations, the correlation of TST with
the new generation of IFN-g-based assays has not been very
good, especially in high TB burden areas, where globally the
number of individuals positive by the TST is much higher than
by the IFN-g assays, reflecting the low specificity of TST in
this setting.19,25—27 On the other hand in a study conducted
among HIV-positive individuals with a similar moderate level
of immunosuppression as in this study, the agreement
between the QFT-G and TST was better than in the HIV-
negative.19 Why a better correlation is obtained in HIV-
positive individuals than in immunocompetent subjects is
not clear. An explanatory hypothesis could be that eventually
the immunosuppression secondary to HIV infection could
differentially affect the cellular immune response responsi-
ble for TST and BCG or environmental mycobacteria
cross-reaction, but the response to previous exposure to
M. tuberculosis infection is preserved until later stages of
HIV infection.
Data on the prevalence of latent TB by a test other than
the TST in the HIV-infected has not been published before in
Chile. Our finding of 15% of positive individuals by the more
specific QFT-G test highlights the necessity of maintaining a
good screening program among this susceptible population.
Whether this screening program should be based on request-
ing the TSTand a chest X-ray at the moment of HIV diagnosis
confirmation, as is the local practice at present, is subject to
debate. The presence of past TB signs in a chest X-ray was not
a predictor for any positive latent TB test in this study.
However, the chest X-ray may remain of value in excluding
active TB before starting TB chemoprophylaxis.
Even if in this study QFT-G contributed to the detection of
an extra 8% of cases than the TST, this margin may not be
sufficient to support its implementation worldwide as a
screening test when considering its technical requirements
and its higher cost. Furthermore, intra-assay variability has
been found with repeated testing of positive QFTsamples and
this has raised concern about QFT reproducibility in gen-
eral.28 Besides, the only strategy that has been shown so
far to decrease the incidence of TB is chemoprophylaxis in
the TST-positive and QFT-G still needs to be validated by
prospective studies for this purpose.29
As one of the limitations of this study, we did not exclude
subjects who may have received isoniazid preventive ther-
apy. It has been shown that previous TB chemoprophylaxis
can affect the response of IFN-g tests.30,31 However, only 28
subjects reported having had a previous TSTamong whom no
more than 15% (n = 4.2) were expected to have had positive
test results based on previous reports in Chile.9 Nevertheless
we should consider that the prevalence of QFT-G positive
tests could have been slightly underestimated.
Another drawback of the study is that we did not include
individuals with severe immunosuppression (CD4 count under
Detection of latent TB in HIV-positive individuals, Chile 651100). We considered that we would be unable to compare the
tests in such a situation, as the results of the TSTwould have
been difficult to decipher because of profound underlying
anergy. Future studies should define the performance of QFT-
G in this group of patients.
This study supports the use of the TST for diagnosing
latent TB in HIV-positive individuals in countries having low
TB global prevalence, even if BCG is widely administered.
The TST remains simpler to perform and is less expensive,
and in this low TB setting resulted in a high rate of
ratification of positive results by QFT-G. However, QFT-G
appears to be a more sensitive tool in subjects with more
advanced immunosuppression, although the lower limit of
CD4 count has not been established nor has a way of
adjusting the amount of IFN-g to the concentration of T
lymphocytes in each blood sample. More studies are also
needed to determine whether the agreement between TST
and QFT-G is effectively better in HIV-positive subjects in
low TB settings.
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